The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma, primary tumors, and sites of metastasis.
 
Veronica Placencio-Hickok
Research Funding - Halozyme
Patents, Royalties, Other Intellectual Property - Patent 17814046.3-1111 PCT/US2017037558. Bhowmick NA, Placencio V, Agarwal A., Smith B. Sensitization of tumors to therapies through endoglin antagonism (Inst)
 
Marie Lauzon
No Relationships to Disclose
 
Natalie Moshayedi
No Relationships to Disclose
 
Michelle Guan
No Relationships to Disclose
 
Sungjin Kim
No Relationships to Disclose
 
Stephen Jacob Pandol
Leadership - Avenzoar
Stock and Other Ownership Interests - Avenzoar; Lucid Sciences; Phyteau
Consulting or Advisory Role - Empirico; Kezar Life Sciences
Patents, Royalties, Other Intellectual Property - Patents and patents pending with Cedars-Sinai Medical Center, University of California, Los Angeles, California Institute of Technology and Avenzoar Pharmaceuticals.
 
Brent K Larson
Research Funding - Halozyme
 
Jun Gong
Honoraria - Amgen; Astellas Pharma; Clinical Congress Consultants; Elsevier; Exelixis; QED Therapeutics
Consulting or Advisory Role - Amgen; Astellas Pharma; Clinical Congress Consultants; Elsevier; Exelixis; QED Therapeutics
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Abbvie; Celgene; Eisai; Ipsen; Novartis; Perthera
Research Funding - Ipsen
Travel, Accommodations, Expenses - Halozyme
 
Arsen Osipov
No Relationships to Disclose